Dihydrotachysterol
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Dihydrotachysterol - a means of regulating metabolic processes. Regulator of calcium and phosphorus metabolism. Dihydrotachysterol increases calcium absorption in the intestines, thereby increasing its level in the blood. The drug also increases the excretion of inorganic phosphorus by the kidneys. Dihydrotachysterol can be used for a long time without developing the effects of overdose or tolerance.
The effect of the drug appears faster at the beginning of treatment and less long after the end of the course than that of vitamin D, thereby reducing the risk of drug accumulation in the body and the development of hypercalcemia. Dihydrotachysterol may exhibit a toxic effect at a dose of about 25 mg per day, which is expressed by symptoms of hypercalcemia. Does not cause addiction.
Indications
Hypoparathyroidism (idiopathic and postoperative), pseudohypoparathyroidism, tetany (muscle cramps caused by hypocalcemia), bone diseases caused by vitamin D deficiency
Composition
1 bottle contains:
Active substance: dihydrotachysterol - 1 mg;
Excipients: refined deodorized sunflower oil or refined soybean oil deodorized to 1 ml.
No customer reviews for the moment.
Dosage and Administration
When ingestion daily dose is 0.25-1.5 mg. The frequency of use depends on the indications and concentrations of calcium in the blood and urine.
Adverse reactions
From the digestive system: anorexia, nausea, vomiting, diarrhea; when used in high doses - biliary dyskinesia.
Since the cardiovascular system: heartbeat; rarely - cardiac arrhythmias.
Metabolism: thirst, tissue calcification.
From the urinary system: with long-term therapy - impaired renal function.
Other: pallor of the skin, headache.
Contraindications
Hypercalcemia, hypervitaminosis D, hypersensitivity to dihydrotachysterol and other preparations of vitamin D.
Drug interactions
While taking dihydrotachysterol with vitamin D, as well as with drugs and dietary supplements containing calcium, hypercalcemia may develop.
At the same time taking dihydrotachysterol with thiazide diuretics and rifampicin, hypercalcemia may occur.
Dihydrotachysterol enhances the action of cardiac glycosides and calcium antagonists. When taken concomitantly with cardiac glycosides or calcium antagonists with dihydrotachysterol, it is possible to reduce the dose of the latter.
Barbiturates (phenobarbital), antiepileptic drugs [phenytoin (difenin), carbamazepine (finlepsin), primidone (hexamidine)], anion exchange resins (colestiramine, colestipol) and vaseline oil weaken the pharmacological action of dihydrotachisterol.
If, while taking dihydrotachysterol, thyroxin is simultaneously treated, then after it is canceled, hypercalcemia may develop.
Special instructions
Use with caution in patients with urolithiasis.
Not recommended simultaneous use with other vitamins of group D, calcium preparations, parathyroid agents.
Dihydrotachysterol should not be used in patients with allergic reactions to nuts (including peanuts).
When applied on the background of thyroid hormone replacement therapy, correction of the dihydrotachysterol dosing regimen may be required.
- Experimental Study of the Effects of Dietressa, a New Weight-Reducing Drug
- Differences in the bioavailability of dihydrotachysterol preparations
- Effect of dihydrotachysterol on bone tissue in rats with experimental renal insufficiency
- Comparison of the effects of vitamin D3, dihydrotachysterol, and parathormone on calcium kinetics in the rat
- Sensitive fluorescence reaction for vitamins D and dihydrotachysterol
- Experimental Production of Cutaneous Calcinosis and Sclerosis with Dihydrotachysterol (AT-10) 1
- Experimental Production of Cutaneous Calcinosis and Sclerosis with Dihydrotachysterol (AT-10) 1
- The effect of polyphloretin phosphate, polyoestradiol phosphate, a diphosphonate and a polyphosphate on calcification induced by dihydrotachysterol in skin, aorta and kidney of rats
- Effect of heat on serum thyroxin and thyrotropin and its modification by dihydrotachysterol
- CRYSTALLINE DIHYDROTACHYSTEROL (DYGRATYL®) IN THE TREATMENT OF HYPOPARATHYROIDISM
- SERUM CONCENTRATIONS OF DIHYDROTACHYSTEROL-2 IN THE TREATMENT OF OSTEOPOROSIS AND HYPOPARATHYROIDISM
- THE LOCALIZATION OF TETRACYCLINE IN THE METASTATIC CALCIFICATIONS IN THE STOMACH OF RAT INDUCED BY OVERDOSAGE OF DIHYDROTACHYSTEROL AND VITAMIN D3
- The Fluorescence of Tetracycline in Rats Treated with Dihydrotachysterol
- Metastatic Calcification in Experimental Overdosage of Dihydrotachysterol in Rats : Effect of Tetracycline, DOCA and Cortisone
- METABOLIC EFFECTS OF DIHYDROTACHYSTEROL
- Licht- und elektronenoptische Untersuchungen zur unspezifischen Organkalzinose nach Verabreichung von Dihydrotachysterol (DHT) an Ratten
- Sensitization by dihydrotachysterol (DHT) and calcium acetate for the induction of cardiac lesions by various agents
- Sensitization by dihydrotachysterol (DHT) for induction of cardiac lesions by various agents∗
- The effects of dihydrotachysterol and ferric dextran upon the periodontium in the rat
- Dihydrotachysterol induction of intestinal calcium-binding activity in the chick
- The gas chromatography of calciferol, dihydrotachysterol and cholesterol
- The response to 1,25-dihydroxycholecalciferol and to dihydrotachysterol in adult-onset hypophosphataemic osteomalacia
- Comparison of the biological effectiveness of calcitriol and dihydrotachysterol
- A prospective double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol